Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report describes a case of universal alopecia in a patient with rheumatoid arthritis while using adalimumab and leflunomide, suggesting a potential link between these drugs and alopecia areata.

This study reports two cases of Alopecia Universalis as a secondary autoimmune manifestation following Alemtuzumab treatment, highlighting the importance of screening and monitoring for such autoimmune responses.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This case report describes a patient in whom vitiligo was induced by diphenylcyclopropenone treatment for alopecia universalis, highlighting the potential overlap of susceptibility genes between the two conditions.

This letter discusses alopecia universalis and Kallman’s Syndrome, and offers no new clinical results.

In this case report, the researchers observed that a woman with longstanding Alopecia Universalis, who had not responded to various treatments, experienced hair regrowth and improved quality of life after two years of individualized homeopathic treatment centered around Natrum Muriaticum.

Azathioprine may be an effective treatment for severe hair loss.

This case report describes alopecia universalis-like hair loss occurring in two patients with cutaneous T cell lymphoma, providing clinical, dermoscopic, and pathologic features to help differentiate it from alopecia areata universalis.

This study presents a reported case where dupilumab treatment for atopic dermatitis led to improvement in alopecia universalis.

This case report describes irreversible alopecia universalis following discontinuation of Peg-IFN/RBV treatment for chronic hepatitis C, highlighting potential autoimmune side effects of interferon-based therapies.

This case study describes a rare instance of alopecia universalis in a Japanese patient following an mRNA COVID-19 vaccination.

This report describes a case of severe hair loss with accompanying thyroid issues and eczema that improved noticeably after individualized homeopathic treatment, following unsuccessful previous methods, as observed at Dr Batra’s® Homeopathy Clinic.

This case study describes a man with long-standing alopecia universalis who experienced hair regrowth after taking testosterone, chorionic gonadotropin, and DHEA-S.

This study identified a missense mutation in the human hairless gene associated with a rare form of recessively inherited alopecia universalis, pinpointed on chromosome 8p12.

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

This case report describes an HIV-infected patient on HAART who developed autoimmune diseases, including alopecia universalis and Graves' disease, associated with immune restoration after CD4 cell count increases.

In this study, serum from patients with alopecia areata or universalis did not affect hair growth in transplanted scalp skin grafts on nude mice, despite increased deposition of immunoreactants.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.

This study reviewed treatment options for alopecia areata totalis and universalis, finding no completely effective therapy. Promising treatments with quality data include diphenylcyclopropenone, squaric acid dibutylester, and photodynamic therapy, but larger, high-quality trials are needed.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.